Abstract
Objective
Breast cancer patients often benefit from adjuvant chemotherapy, a protocol whose
effectiveness is accompanied by disabling adverse effects. The aim of this controlled
clinical study was to determine the impact of visceral osteopathy on the incidence
of nausea/vomiting, constipation and overall quality of life (QoL) in women operated
for breast cancer and undergoing adjuvant chemotherapy in Centre Georges François
Leclerc, CGFL.
Study Design
Ninety-four women operated for a breast cancer stage 1–3, in complete resection and
to whom a 3 FEC 100 chemotherapy was prescribed, were randomly allocated to experimental
or placebo group. Experimental group underwent a visceral osteopathic technique and
placebo group was subjected to a superficial manipulation after each chemotherapy
cycle. Rate of grade ≥1 nausea/vomiting or constipation, on the first 3 cycles of
FEC 100, were reported. QoL was evaluated using the EORTC QLQ-C30 questionnaire.
Results
Rate of nausea/vomiting episodes of grade ≥1 was high in both experimental and placebo
group. Constipation episodes of grade ≥1 were also frequent. No significant differences
were found between the two groups concerning the rate of nausea/vomiting (p = 0.569)
or constipation (p = 0.204) according to clinician reported side-effects but patient
reported impact of constipation and diarrhoea on quality of life was significantly
lower in experimental group (p = 0.036 and p = 0.038, respectively).
Conclusion
Osteopathy does not reduce the incidence of nausea/vomiting in women operated for
breast cancer and undergoing adjuvant chemotherapy. In contrast, patient reported
digestive quality of life was significantly ameliorated by osteopathy. Clinicaltrials.gov
Identifier: NCT02840890.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of Obstetrics and Gynecology and Reproductive BiologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J Clin. 2018; https://doi.org/10.3322/caac.21492
- Long-term cardiac follow-up in relapse-free patients after six courses of fluorouracil, epirubicin, and cyclophosphamide, with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French adjuvant study group.J Clin Oncol. 2004; 22: 3070-3079https://doi.org/10.1200/JCO.2004.03.098
- Comission de Transparence. Avis TAXOTERE (docétaxel).HAS- Direction de l’Evaluation Médicale, Economique et de Santé Publique, 2006
- Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial.J Clin Oncol Off J Am Soc Clin Oncol. 2001; 19: 602-611https://doi.org/10.1200/JCO.2001.19.3.602
- Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 trial.J Clin Oncol. 2006; 24: 5664-5671https://doi.org/10.1200/JCO.2006.07.3916
- Comission de la transparence. Avis aprépitant.HAS- Direction de lEvaluation Médicale, Economique et de Santé Publique, 2016
- MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients.Ann Oncol. 2016; 27: v119-33https://doi.org/10.1093/annonc/mdw270
- Acupressure for nausea: results of a pilot study.Oncol Nurs Forum. 2000; 27: 41-47
- Massage relieves nausea in women with breast cancer who are undergoing chemotherapy.J Altern Complement Med N Y N. 2007; 13: 53-57https://doi.org/10.1089/acm.2006.6049
- Évaluation de l’efficacité d’un traitement ostéopathique sur les effets secondaires et la qualité de vie de patients sous chimiothérapie Essai clinique multicentrique randomisé.2012: 8
- Ostéopathie et effets secondaires digestifs de la chimiothérapie.ApoStill. 2007; : 21-28
- The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology.J Natl Cancer Inst. 1993; 85: 365-376
- Common terminology criteria for adverse events (CTCAE) V.4.03.2010: 80
- Breakthrough chemotherapy-induced nausea and vomiting: report of a nationwide survey by the CINV Study Group of Japan.Int J Clin Oncol. 2017; 22: 405-412https://doi.org/10.1007/s10147-016-1069-7
- Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy.Support Care Cancer Off J Multinatl Assoc Support Care Cancer. 2010; 18: 1171-1177https://doi.org/10.1007/s00520-009-0737-9
- Prognostic factors for chemotherapy induced nausea and vomiting.Eur J Pharmacol. 2014; 722: 192-196https://doi.org/10.1016/j.ejphar.2013.10.015
- The perceptions and experiences of osteopathic treatment among cancer patients in palliative care: a qualitative study.Support Care Cancer. 2018; 26: 3627-3633https://doi.org/10.1007/s00520-018-4233-y
- Cancer chemotherapy-induced diarrhoea and constipation: mechanisms of damage and prevention strategies.Support Care Cancer. 2006; 14: 890-900https://doi.org/10.1007/s00520-006-0040-y
- Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron.Cancer. 2003; 98: 2473-2482https://doi.org/10.1002/cncr.11817
C. Cherwin, L. Nakad, A. Albashayreh. Systematic Review of Nonpharmacologic Approaches for the Management of Gastrointestinal Symptoms n.d.:21.
- Osteopathic management of chronic constipation in women patients. Results of a pilot study.Clin Res Hepatol Gastroenterol. 2017; 41: 602-611https://doi.org/10.1016/j.clinre.2016.12.003
- The effect of osteopathic treatment on chronic constipation – a pilot study.Int J Osteopath Med. 2010; 13: 17-23https://doi.org/10.1016/j.ijosm.2009.10.002
- Differences in urologist and patient assessments of health related quality of life in men with prostate cancer: results of the CaPSURE database.J Urol. 1998; 159: 1988-1992
- Assessing health-related quality of life in palliative care: comparing patient and physician assessments.Eur J Cancer. 2006; 42: 1159-1166https://doi.org/10.1016/j.ejca.2006.01.032
- Clinician versus nurse symptom reporting using the National Cancer Institute-common Terminology Criteria for adverse events during chemotherapy: results of a comparison based on patient’s self-reported questionnaire.Ann Oncol Off J Eur Soc Med Oncol. 2009; 20: 1929-1935https://doi.org/10.1093/annonc/mdp287
- Patient versus clinician symptom reporting using the National Cancer institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study.Lancet Oncol. 2006; 7: 903-909https://doi.org/10.1016/S1470-2045(06)70910-X
- Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials.J Clin Oncol. 2015; 33: 910-915https://doi.org/10.1200/JCO.2014.57.9334
- How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the quality-of-life questionnaire C30.J Clin Oncol. 2004; 22: 3485-3490https://doi.org/10.1200/JCO.2004.03.025
- World Health Organization.Benchmarks for training in osteopathy. 2010: 2010
Article info
Publication history
Published online: August 12, 2019
Accepted:
August 9,
2019
Received in revised form:
August 6,
2019
Received:
July 3,
2019
Identification
Copyright
© 2019 Elsevier B.V. All rights reserved.
